Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
15.22 CHF | +1.20% | +1.06% | -19.89% |
17/04 | AARDEX Group announced that it has received funding from medmix AG | CI |
16/04 | Medmix Unit Enters Japanese Distribution Deal for PiccoJect Product | MT |
Valuation
Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|
Capitalization 1 | 1,863 | 720.1 | 776.7 | 620.7 | - | - |
Enterprise Value (EV) 1 | 1,974 | 876.8 | 776.7 | 781.1 | 729.5 | 685.9 |
P/E ratio | 42.2 x | 62.9 x | 1,900 x | 18.3 x | 12.1 x | 8.99 x |
Yield | 1.11% | 2.84% | - | 4.93% | 5.42% | 7.23% |
Capitalization / Revenue | 4.07 x | 1.51 x | 1.6 x | 1.19 x | 1.1 x | 1.03 x |
EV / Revenue | 4.32 x | 1.84 x | 1.6 x | 1.5 x | 1.3 x | 1.13 x |
EV / EBITDA | 17.7 x | 12.4 x | 10.4 x | 6.91 x | 5.62 x | - |
EV / FCF | 34.3 x | 78.3 x | - | 15.7 x | 17.6 x | - |
FCF Yield | 2.91% | 1.28% | - | 6.35% | 5.69% | - |
Price to Book | 3.48 x | 1.44 x | - | 1.29 x | 1.17 x | 1.16 x |
Nbr of stocks (in thousands) | 41,262 | 40,914 | 40,877 | 40,782 | - | - |
Reference price 2 | 45.16 | 17.60 | 19.00 | 15.22 | 15.22 | 15.22 |
Announcement Date | 22/02/22 | 21/02/23 | 22/02/24 | - | - | - |
Income Statement Evolution (Annual data)
Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|---|
Net sales 1 | 351.3 | 457.3 | 477.1 | 486.6 | 520.6 | 563 | 605 |
EBITDA 1 | - | 111.7 | 70.7 | 74.4 | 113.1 | 129.9 | - |
EBIT 1 | - | 59.9 | 19.6 | 16 | 56.59 | 67.75 | - |
Operating Margin | - | 13.1% | 4.11% | 3.29% | 10.87% | 12.03% | - |
Earnings before Tax (EBT) | - | 51.3 | 12.2 | - | - | - | - |
Net income 1 | 9.6 | 44 | 11.6 | 0.3 | 34.28 | 51.78 | 69.89 |
Net margin | 2.73% | 9.62% | 2.43% | 0.06% | 6.59% | 9.2% | 11.55% |
EPS 2 | - | 1.070 | 0.2800 | 0.0100 | 0.8309 | 1.258 | 1.694 |
Free Cash Flow 1 | - | 57.5 | 11.2 | - | 49.64 | 41.49 | - |
FCF margin | - | 12.57% | 2.35% | - | 9.53% | 7.37% | - |
FCF Conversion (EBITDA) | - | 51.48% | 15.84% | - | 43.9% | 31.94% | - |
FCF Conversion (Net income) | - | 130.68% | 96.55% | - | 144.79% | 80.14% | - |
Dividend per Share 2 | - | 0.5000 | 0.5000 | - | 0.7500 | 0.8250 | 1.100 |
Announcement Date | 16/08/21 | 22/02/22 | 21/02/23 | 22/02/24 | - | - | - |
Income Statement Evolution (Quarterly data)
Fiscal Period: December | 2021 S1 | 2021 S2 | 2022 S1 | 2022 S2 | 2023 S1 |
---|---|---|---|---|---|
Net sales 1 | 228.3 | 229 | 250.6 | 226.5 | 248.1 |
EBITDA 1 | - | 54.8 | 56.5 | 14.2 | 40 |
EBIT 1 | - | 28.6 | 31.3 | -11.7 | 14.5 |
Operating Margin | - | 12.49% | 12.49% | -5.17% | 5.84% |
Earnings before Tax (EBT) | - | - | - | - | - |
Net income 1 | 22.7 | 21.3 | 23.8 | -12.2 | 7.3 |
Net margin | 9.94% | 9.3% | 9.5% | -5.39% | 2.94% |
EPS 2 | - | - | 0.5800 | -0.3000 | 0.1800 |
Dividend per Share | - | - | - | - | - |
Announcement Date | 04/11/21 | 22/02/22 | 21/07/22 | 21/02/23 | 21/07/23 |
Balance Sheet Analysis
Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|---|
Net Debt 1 | - | 111 | 157 | - | 160 | 109 | 65.2 |
Net Cash position 1 | - | - | - | - | - | - | - |
Leverage (Debt/EBITDA) | - | 0.9928 x | 2.216 x | - | 1.419 x | 0.8372 x | - |
Free Cash Flow 1 | - | 57.5 | 11.2 | - | 49.6 | 41.5 | - |
ROE (net income / shareholders' equity) | - | 10.7% | 8.59% | - | 7.13% | 11.3% | 13.2% |
ROA (Net income/ Total Assets) | - | - | - | - | - | - | - |
Assets 1 | - | - | - | - | - | - | - |
Book Value Per Share 2 | - | 13.00 | 12.20 | - | 11.80 | 13.00 | 13.10 |
Cash Flow per Share | - | 2.120 | 1.160 | - | - | - | - |
Capex 1 | - | 29.8 | 36.4 | - | 48.6 | 47.2 | 50.4 |
Capex / Sales | - | 6.52% | 7.63% | - | 9.34% | 8.39% | 8.34% |
Announcement Date | 16/08/21 | 22/02/22 | 21/02/23 | 22/02/24 | - | - | - |
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-19.89% | 679M | |
-2.31% | 187B | |
-3.20% | 106B | |
-5.04% | 66.9B | |
+0.20% | 49.45B | |
+17.29% | 48B | |
+4.06% | 40.84B | |
+2.07% | 26.48B | |
+2.36% | 26.25B | |
+12.96% | 24.62B |
- Stock Market
- Equities
- MEDX Stock
- Financials medmix AG